Bank of America
LTRN icon

Bank of America’s Lantern Pharma LTRN Stock Holding History

Bank of America’s Portfolio LTRN Stock Details LTRN Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q1 		– Sell
-7
Closed -$21 – 6398
2025
Q4 		$21 Buy
7
+1
+17% +$4 ﹤0.01% 7114
2025
Q3 		$26 Sell
6
-71
-92% -$296 ﹤0.01% 8134
2025
Q2 		$243 Buy
77
+9
+13% +$30 ﹤0.01% 7806
2025
Q1 		$241 Buy
68
+3
+5% +$12 ﹤0.01% 7650
2024
Q4 		$207 Hold
65
– – ﹤0.01% 7577
2024
Q3 		$239 Sell
65
-4
-6% -$16 ﹤0.01% 7529
2024
Q2 		$322 Buy
+69
New +$415 ﹤0.01% 7447
2024
Q1 		– Sell
-5
Closed -$21 – 8004
2023
Q4 		$21 Buy
+5
New +$18 ﹤0.01% 7644
2023
Q1 		– Sell
-8
Closed -$48 – 8074
2022
Q4 		$48 Buy
+8
New +$40 ﹤0.01% 7805
2022
Q1 		– Sell
-13
Closed – – 8541
2021
Q4 		$0 Sell
13
-5,590
-100% -$51.1K ﹤0.01% 8456
2021
Q3 		$62K Buy
5,603
+3,412
+156% +$44.1K ﹤0.01% 6949
2021
Q2 		$32K Buy
2,191
+2,151
+5,378% +$33.2K ﹤0.01% 6992
2021
Q1 		$1K Buy
+40
New +$701 ﹤0.01% 7319

Other funds holding LTRN

BCM
BIOS Capital Management Fort Worth, Texas $52.9M AUM 30.51% 1-Year Est. Return
VCM
Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM
CM
CM Management Gulf Breeze, Florida $120M AUM 37.12% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
WIM
Westside Investment Management Santa Monica, California $761M AUM 39.85% 1-Year Est. Return
VC
Voss Capital Houston, Texas $1.88B AUM 1.03% 1-Year Est. Return
VFT
Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Bank of America's LTRN Position: Q1 2026 in Review

Bank of America sold out of Lantern Pharma (LTRN) in Q1 2026, closing a stake of 7 shares — an estimated $21 sold.

Bank of America first reported a position in LTRN in Q1 2021 and held it in 13 quarters. The position peaked at $62K in Q3 2021. 33 funds tracked by Wall St. Rank hold LTRN as of Q1 2026.

  • Bank of America reported no remaining Lantern Pharma position as of Q1 2026 after selling out during the quarter.
  • Bank of America sold 7 Lantern Pharma shares in Q1 2026, an estimated $21.
  • Bank of America first reported a position in Lantern Pharma in Q1 2021 and held it in 13 quarters.
  • Bank of America's Lantern Pharma position peaked at $62K in Q3 2021.
  • 33 funds tracked by Wall St. Rank held Lantern Pharma as of Q1 2026.

Based on Bank of America's 13F filing for Q1 2026, filed 18 May 2026.